The Centessa Pharmaceuticals plc (CNTA) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and related exhibits. As a Nasdaq-listed issuer with ordinary shares and American Depositary Shares registered under Section 12(b) of the Exchange Act, Centessa files documents that describe material events, financing transactions, governance matters and other information relevant to CNTA shareholders.
Recent Forms 8‑K detail items such as underwriting agreements for public offerings of American Depositary Shares, an amended and restated at-the-market sales agreement, financial results for quarterly periods, and the clearance of an Investigational New Drug (IND) application for ORX142. Filings also cover outcomes of the company’s annual general meeting, including director elections, auditor re-appointment and share allotment authorities, as well as executive employment arrangements reported under Item 5.02.
Through this page, users can review how Centessa reports progress and risks around its clinical-stage orexin receptor 2 (OX2R) agonist pipeline, capital-raising activities, and other significant corporate actions. Forms 8‑K that reference press releases often include clinical and financial updates, while accompanying exhibits such as sales agreements, underwriting agreements and legal opinions provide additional detail on transaction structures and securities law matters.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, sections and implications, helping readers quickly understand complex documents such as offering-related 8‑Ks and governance disclosures. Investors can use this resource to monitor CNTA’s regulatory reporting history, track new filings as they appear on EDGAR in near real time, and identify information relevant to their own analysis of the company.
On 20 June 2025 Centessa Pharmaceuticals plc (ticker CNTA) held its 2025 Annual General Meeting with 124,956,837 ordinary shares represented out of 133,719,291 entitled to vote, establishing quorum.
Shareholders approved every item on the agenda:
- Director re-appointments: Arjun Goyal (116.90 m for; 0.46 m against) and Samarth Kulkarni (97.75 m for; 19.61 m against).
- Auditors: KPMG LLP re-appointed as UK statutory auditor and ratified as US independent registered public accounting firm (≈125 m for; <0.01 m against).
- Auditor remuneration: Audit Committee authorised to set fees (117.13 m for).
- FY-2024 accounts: Accounts adopted; directors confirmed no dividend for FY-2024.
- Remuneration matters: Advisory vote on 2024 directors remuneration report and approval of new remuneration policy both passed.
- Share allotment authority: Directors authorised under Companies Act s.551 to allot shares/rights up to £133,184 nominal (104.16 m for; 12.98 m against).
- Special resolution: Pre-emption rights disapplied for the same nominal amount (98.23 m for; 18.90 m against).
No broker non-votes were recorded and the filing contains no disclosures on earnings, major transactions or strategic shifts. The report is primarily routine corporate-governance in nature.